---
schema_version: "secwatch.filing_event.v1"
accession: "0000872589-26-000014"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:36:43.969769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut

## Summary
- Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.
- EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.
- Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.
- New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.
- FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption.

## SEC filing metadata
- accession: 0000872589-26-000014
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/0000872589-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/regn-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000872589-26-000014
- JSON: https://secwatch.observer/filing/0000872589-26-000014.json
- Plain text: https://secwatch.observer/filing/0000872589-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.